Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer

Incorporation of androgen receptor antagonists into the management of M0 prostate cancer

Topic 1: PSA doubling time and time to initiation of androgen deprivation therapy (ADT) for patients with nonmetastatic prostate cancer
Topic 2: Considerations for administering secondary hormonal therapy to patients with nonmetastatic castration-resistant prostate cancer (CRPC) and PSA-only disease progression
Topic 3: Effect of PSA doubling time on prognosis for patients with M0 disease; risk of progression with secondary hormonal therapy
Topic 4: Choice of secondary hormonal therapy for patients with nonmetastatic CRPC and PSA-only progression
Topic 5: Treatment approach and risk of metastasis for patients with a PSA doubling time of 10 months
Topic 6: Perspective on the use of intermittent ADT for patients with prostate cancer
Topic 7: Side effects and tolerability of androgen receptor antagonists

Management of metastatic hormone-sensitive prostate cancer (HSPC)

Topic 8: Choice of systemic therapy for a young patient with HSPC and moderately symptomatic, widespread bone metastases
Topic 9: Therapeutic approach for an older patient with HSPC and moderately symptomatic, widespread bone metastases
Topic 10: Selection of therapy for patients with HSPC and asymptomatic, low-volume metastases

Current and future management of metastatic CRPC (mCRPC)

Topic 11: Therapeutic approach for patients who develop mCRPC while receiving ADT
Topic 12: Choice of treatment for patients with mCRPC who experience disease progression on abiraterone; testing for AR-V7 (androgen receptor splice variant 7)

Ongoing evaluation of PARP inhibitors in the management of metastatic prostate cancer

Topic 13: Germline BRCA mutation testing for patients with prostate cancer
Topic 14: Use of PARP inhibitors for patients with metastatic prostate cancer and a germline BRCA mutation

Bone-targeted therapies for mCRPC

Topic 15: Efficacy and safety of radium-223 dichloride in patients with mCRPC
Topic 16: Integration of radium-223 into the clinical management of mCRPC
Topic 17: Use of PSMA (prostate-specific membrane antigen)-binding ligands for targeted treatment of prostate cancer
Emmanuel S Antonarakis, MD
Associate Professor of
Oncology and Urology
Johns Hopkins Sidney Kimmel
Comprehensive Cancer Center
Baltimore, Maryland
A Oliver Sartor, MD
CE and Bernadine Laborde
Professor for Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana
Howard I Scher, MD
D Wayne Calloway Chair in
Urologic Oncology
Center for Mechanism Based Therapy
Head, Biomarker Development Initiative
Member and Attending Physician
Genitourinary Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York
Matthew R Smith, MD, PhD
Claire and John Bertucci
Endowed Chair in Genitourinary Cancers
Professor of Medicine
Harvard Medical School
Genitourinary Malignancies Program
Massachusetts General Hospital
Cancer Center
Boston, Massachusetts
Cora N Sternberg, MD
Clinical Director
Englander Institute for Precision Medicine
Weill Cornell Medicine
New York, New York
Neil Love, MD
Research To Practice
Miami, Florida